The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2 , dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Diabetic Foot Ulcer Trial to Initiate in 1H26 ...

Pelvic organ prolapse (POP) represents a highly prevalent condition among women, particularly following childbirth and during aging, with recurrence ...

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...

Jen Davis (left) and Bella Reichardt (right) conducting research in a lab for genetic engineering of heart fibroblasts.at the UW Medicine Institute for Stem Cell and Regeneration Medicine. Fibroblasts ...

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved ...

In a collaboration between several labs at UNC Lineberger, researchers have defined cancer-associated fibroblast (CAF) subtypes that are clinically robust, prognostic, and predictive of immunotherapy ...

Add Yahoo as a preferred source to see more of our stories on Google. Dense fibrous connective tissue Many of the body's processes slow down or falter as we get older, including tissue regeneration.

As we age, we don’t recover from injury or illness like we did when we were young. But new research from UC San Francisco has found gene regulators that turn genes on and off that could restore the ...